Cargando…

Growth hormone insensitivity: Mexican case report

Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Castilla-Cortazar, I, De Ita, J R, Aguirre, G A, García–Magariño, M, Martín-Estal, I, Lara-Diaz, V J, Elizondo, M I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682564/
https://www.ncbi.nlm.nih.gov/pubmed/29147569
http://dx.doi.org/10.1530/EDM-17-0126
_version_ 1783278120360476672
author Castilla-Cortazar, I
De Ita, J R
Aguirre, G A
García–Magariño, M
Martín-Estal, I
Lara-Diaz, V J
Elizondo, M I
author_facet Castilla-Cortazar, I
De Ita, J R
Aguirre, G A
García–Magariño, M
Martín-Estal, I
Lara-Diaz, V J
Elizondo, M I
author_sort Castilla-Cortazar, I
collection PubMed
description Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy. LEARNING POINTS: Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice. Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable. Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise.
format Online
Article
Text
id pubmed-5682564
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-56825642017-11-16 Growth hormone insensitivity: Mexican case report Castilla-Cortazar, I De Ita, J R Aguirre, G A García–Magariño, M Martín-Estal, I Lara-Diaz, V J Elizondo, M I Endocrinol Diabetes Metab Case Rep Insight into Disease Pathogenesis or Mechanism of Therapy Herein, we present a 14-year-old patient with short stature (134 cm) referred from Paediatrics to our department for complementary evaluation since growth hormone (GH) treatment failed to show any improvement. He was born premature and small for gestational age. Genital examination classified the patient as Tanner I–II with small penis and testicular size for his age. Biochemical analyses revealed normal GH levels with low serum insulin-like growth factor-1 (IGF-1). Molecular diagnosis confirmed several mutations in IGF1R and IGFALS, and so he was diagnosed with Laron Syndrome or GH insensibility and treated with IGF-1 substitutive therapy. LEARNING POINTS: Evaluation of the GH/IGF-1 axis when short stature does not respond to conservative treatment must be included in the ordinary practice. Laron Syndrome real incidence should be calculated once undiagnosed cases arise, as treatment, due to lack of market, is unaffordable. Even when adulthood is reached, and no longitudinal growth can be achieved, still IGF-1 treatment in Laron Syndrome patients should be pursued as metabolic and protective derangements could arise. Bioscientifica Ltd 2017-11-09 /pmc/articles/PMC5682564/ /pubmed/29147569 http://dx.doi.org/10.1530/EDM-17-0126 Text en © 2017 The authors http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Insight into Disease Pathogenesis or Mechanism of Therapy
Castilla-Cortazar, I
De Ita, J R
Aguirre, G A
García–Magariño, M
Martín-Estal, I
Lara-Diaz, V J
Elizondo, M I
Growth hormone insensitivity: Mexican case report
title Growth hormone insensitivity: Mexican case report
title_full Growth hormone insensitivity: Mexican case report
title_fullStr Growth hormone insensitivity: Mexican case report
title_full_unstemmed Growth hormone insensitivity: Mexican case report
title_short Growth hormone insensitivity: Mexican case report
title_sort growth hormone insensitivity: mexican case report
topic Insight into Disease Pathogenesis or Mechanism of Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682564/
https://www.ncbi.nlm.nih.gov/pubmed/29147569
http://dx.doi.org/10.1530/EDM-17-0126
work_keys_str_mv AT castillacortazari growthhormoneinsensitivitymexicancasereport
AT deitajr growthhormoneinsensitivitymexicancasereport
AT aguirrega growthhormoneinsensitivitymexicancasereport
AT garciamagarinom growthhormoneinsensitivitymexicancasereport
AT martinestali growthhormoneinsensitivitymexicancasereport
AT laradiazvj growthhormoneinsensitivitymexicancasereport
AT elizondomi growthhormoneinsensitivitymexicancasereport